Interestingly, the first approved aptamer medication is an anti‐vascular endothelial growth factor (VEGF) aptamer for inhibiting the growth of abnormal blood vessels in age‐related macular degeneration and diabetic macular edema.[9] The second aptamer‐based drug, which was approved just this year, is also for treating an eye disease called geographical atrophy. The gene discussed is VEGFA; the disease is atrophic macular degeneration.